Navigation Links
Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211
Date:12/3/2009

SAN DIEGO, Dec. 3 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

The interim results demonstrate that a dose proportional pharmacodynamic (PD) effect can be achieved with AM461. Additionally, AM461 Phase 1 data to date demonstrates a good safety profile. AM461 is a back-up to Amira's lead DP2 antagonist, AM211, which has successfully completed Phase 1 clinical studies.

"The AM461 clinical data further strengthens our commitment to the DP2 receptor as a clinical target. Amira now has two structurally distinct, clinical-stage compounds targeting the receptor," said Isabelle DeArmond, Vice President, Clinical Development.

"Our approach to drug development is based upon bringing multiple structurally and metabolically distinct compounds forward in development. In addition to AM211 and AM461, we have additional novel DP2 antagonist molecules in reserve," said Bob Baltera, Chief Executive Officer.

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. A DP2 antagonist has the potential to be disease modifying in these aforementioned conditions. DP2 is also known as CRTH2, or chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and in humans is implicated in Th2-dependent allergic inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.

SOURCE Amira Pharmaceuticals, Inc.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
2. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
3. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
4. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
5. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
6. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
9. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
10. iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology:
(Date:3/27/2017)... Cranbury, NJ (PRWEB) , ... March 27, 2017 ... ... publication of cutting-edge news, research and conference coverage on veterinary medicine, announces the ... The inaugural issue will be packaged with the April edition of American Veterinarian™. ...
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... latest products to the Deaf Seniors of America Conference, April 4-7 at the Hotel ... with knowledgeable ASL friendly staff from Harris Communications and to try out the newest ...
Breaking Medicine News(10 mins):